Vinny Pizzuti, MD, MS
banner
vpizzuti.bsky.social
Vinny Pizzuti, MD, MS
@vpizzuti.bsky.social
IM PGY3 at University of Colorado, Future Heme/onc Hopeful, Former Engineer. He/him
I am happy to announce I was selected by @ash.hematology.org to receive the ASH HONORS Award!

Excited for this project studying PET/CT radiomics in DLBCL. Grateful to Dr. Manali Kamdar for her mentorship & ASH!
#ASHAwards #Fight4Hematology
@cudeptofmedicine.bsky.social
@cuhematology.bsky.social
July 16, 2025 at 5:41 PM
Be on the lookout for a manuscript next year further describing our work! Big thanks to @ASH_hematology for allowing me to present and my mentor @majorajay for all the guidance and support!

Check out for more info:
- ashpublications.org/blood/article/…
- bison-pro.org
December 18, 2024 at 11:45 PM
Similar improvements in reducing negative QoL outcomes were observed for active treatment groups at 6 months. Pts receiving cell therapies had temporary worsening of anxiety/depression early in tx but did have improvement in fatigue in our cohort #ASH24 /7
December 18, 2024 at 11:45 PM
For the positive outcomes, surveillance pts saw minimal changes from 0 to 6 months. Pts receiving systemic tx or cell therapies had overall improved measures at 6 mos., but pts receiving chemo had worsened cognitive function at 6 months #ASH24 /6
December 18, 2024 at 11:45 PM
Similarly, PROMIS instruments were able to detect differences between groups, and here we highlight that global physical health and role functioning were higher in patients undergoing active surveillance vs active tx #ASH24 /4
December 18, 2024 at 11:45 PM
Using FACT instruments, we observed significant differences between groups at baseline for lymphoma pts. Interestingly, QoL seemingly improved for pts with lymphoma undergoing active tx (FACT-LYM), but this was not seen with CLL pts (FACT-LEU) #ASH24 /3
December 18, 2024 at 11:45 PM
In our initial feasibility study, we administered PROMIS and FACT instruments to patients in 3 arms longitudinally and sought to determine if we could detect meaningful differences between study groups #ASH24 /2
December 18, 2024 at 11:45 PM
Interested in patient reported outcomes (PROs) in patients with lymphoma? Join me as I recap my poster highlighting our work on the BISON PRO QoL Study presented at #ASH24 #lymsm
December 18, 2024 at 11:45 PM
Really grateful to have had the opportunity to present a poster highlighting my work with @majorajay.bsky.social at #ASH2024 it was a great experience with a great group of people!
December 10, 2024 at 3:51 PM